Swiss pharmaceutica giant Roche is expanding in the field of digital pathology with an agreement to acquire United States firm PathAI. +Get the most important news from Switzerland in your inbox With this acquisition, Roche aims to expand its position in AI-based diagnostic solutions. The purchase price is $750 million plus potential milestone payments of up to $300 million, the company announced. + Why Roche’s supercomputer is a big deal The combination of PathAI’s AI-powered Image Management System (IMS) with Roche’s diagnostic expertise is expected to increase the efficiency of laboratories, accelerate the development of new clinical therapies and enable the discovery of new biomarkers and new diagnostic tools. Roche expects this to be a further step towards personalised medicine. Roche and PathAI already entered into a collaboration in 2021, which was intensified in 2024. Roche expects the acquisition of PathAI to be completed in the second half of the current year, subject to …